Articles - Breast Cancer A specially curated list of peer-reviewed articles discussing the latest advancements in the diagnosis and treatment of patients living with Early Breast Cancer & Metastatic Breast Cancer. Filter by TopicAbemaciclibAdherenceAdiposityAdjuvant TherapyAdjuvant Treatmentadvanced-stage breast cancerAKT inhibitorsAlpelisibAnastrozolearchive 2023Aromatase inhibitorBioavailabilityBody compositionBody imageBone-targeted deliveryBreast CancerCancer-specific promotersCapivasertibCDK inhibitorsCDK4/6CDK4/6 Inhibitor ResistanceCDK4/6 inhibitorsCDK4/6 ToxicityCell cycle inhibitionChemotherapyChitosanClinical TrialsConferenceCRISPRCutaneous ToxicityCyclin-dependent kinases 4/6 inhibitors (CDK4/6i)DalpiciclibDepressionDermatologic toxicitiesDiarrhoeaDisseminated Carcinomatosis of Bone Marrow (DCBM)Dose reductionDrug DeliveryDrug-drug interactionsEarly Breast CancerEarly Breast Cancer Treatment OptionsEducational expectationsEGFREndocrine TherapyEstrogen ReceptorFirst line therapyGene therapyHealth-system specialty pharmacyHematologic toxicityHER2-Negative Breast CancerHormone receptor-positive (HR+)Hormone receptor-positive breast cancer (HR+/HER2- BC)Hormone receptorsHormone-positive metastatic breast cancerHR-positiveHR+/HER2- breast cancerImmune microenvironmentKnowledge gapsLichenoid dermatitisLuminal Breast Cancer (LBC)Machine learningMacrocytosisMeta-analysisMetastatic Breast CancerMyelosuppressionNanocarrierNanoparticlesNanostructured lipid carrierNeoadjuvant therapyNeutropeniaNon-adherenceOral antitumor therapyOsimertinibOverall SurvivalPalbociclibPatentsPathological complete responsePatient perceptionsPatient ProfilePD-1 inhibitorPIK3CAPolypharmacyPrognostic Nutritional Index (PNI)Prognostic signaturesProgression Free SurvivalProgression-free survival (PFS)Quality of lifeRadiation therapyRadiotherapyRetrospective analysisRibociclibRisk StratificationSafetySocial supportSONIA trialSpartalizumabSubacute Cutaneous LupusSurvival outcomesTherapeutic ResponseToxicityTreatmentTreatment preferencesTrilaciclibTriple-Negative Breast Cancer (TNBC)Tumor microenvironment (TME)Understanding Breast Cancer Real-world data analysis of safety and efficacy of palbociclib in HR positive, HER-2 negative MBC patients, at tertiary care hospital at Middle East, Saudi Arabia. READ MORE Association of initial abemaciclib dosing with duration of medication use in patients with stage II/III breast cancer on endocrine therapy. READ MORE A single center experience of PIK3CA and AKT inhibitors in patients with hormone receptor positive metastatic breast cancer. READ MORE CDK inhibitors and radiation therapy in breast cancer: Hematologic toxicity and survival implications. READ MORE Palbociclib-Induced Subacute Cutaneous Lupus READ MORE Incidence and management of diarrhoea associated with abemaciclib and endocrine therapy for hormone-receptor positive, HER2-negative metastatic breast cancer: the UK patients’ experiences READ MORE Perceptions, educational expectations and knowledge gaps of patients with non-metastatic breast cancer regarding radiotherapy: Integrative review READ MORE Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib – Which One, How and For Whom? READ MORE Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor–positive breast cancer READ MORE Understanding the prospective of gene therapy for the treatment of breast cancer READ MORE Novel Estrogen Receptor – Targeted Therapies in Hormone-Receptor Positive Breast Cancer READ MORE Clinician’s guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer READ MORE Application of Bone-Targeted Nanoparticles for Trilaciclib Delivery in Chemotherapy-Induced Myelosuppression READ MORE Cellular interactions within the immune microenvironment underpins resistance to cell cycle inhibition in breast cancers READ MORE A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer READ MORE Association between body composition parameters and treatment-related toxicities in patients with metastatic breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors READ MORE Impact of social support on body image during chemotherapy in patients with breast cancer: The chain mediating role of depression and self-efficacy READ MORE Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer READ MORE Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer READ MORE Valuable predictive power of prognostic nutritional index in metastatic breast cancer patients treated with CDK4/6 inhibitors READ MORE Advances in CDK4 and 6 Inhibitors: Transforming Breast Cancer Treatment READ MORE The SONIA trial shows the power and challenges of academic research READ MORE Novel combination therapy of osimertinib and Tupichinol E in triple-negative breast cancer: Targeting EGFR and CDK4/6 pathways READ MORE Real-World Analysis of Adherence to Abemaciclib and Endocrine Therapy in Women with HR+/HER2− Breast Cancer READ MORE Preparation, Optimization, and in-vitro Release Study of Abemaciclib-Loaded Chitosan Nanocarrier as a New Approach for Breast Cancer Treatment READ MORE Development and Preclinical Assessment of a Palbociclib Nanostructured Lipid Carrier for Potential Breast Cancer Management READ MORE A single-centre retrospective evaluation of potential drug-drug interactions in breast cancer patients undergoing CDK 4/6 inhibitors chemotherapy READ MORE Effect of Nutritional Teaching Program on Knowledge, Practices, Taste Alterations, and Appetite among Breast Cancer Women undergoing Chemotherapy READ MORE Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study READ MORE Circulating CD3+CD8+ T Lymphocytes as Indicators of Disease Status in Patients With Early Breast Cancer READ MORE A Review on Integrating Breast Cancer Clinical Data: A Unified Platform Perspective READ MORE Ultrasonographic accuracy in evaluating response of clipped lymph nodes in targeted axillary dissection in breast cancer READ MORE A windowing-based multi-view u-net for tumor segmentation in cone-beam breast CT READ MORE Integrating clinicopathologic information and dynamic contrast-enhanced MRI for augmented prediction of neoadjuvant chemotherapy response in breast cancer READ MORE GeneXAI: Influential gene identification for breast cancer stages using XAI-based multi-modal framework READ MORE Gene expression profiling for the diagnosis of male breast cancer READ MORE Exploration of crucial stromal risk genes associated with prognostic significance and chemotherapeutic opportunities in invasive ductal breast carcinoma READ MORE Palbociclib-letrozole loaded solid self-nano emulsifying drug delivery system for oral treatment of breast cancer: In-vitro and In-vivo characterization READ MORE First-line endocrine therapy combined with CDK 4/6 inhibitor in disseminated carcinomatosis of bone marrow (DCBM) luminal breast cancer: a case report READ MORE Design, synthesis and characterization of novel thiazolidinone derivatives: Insights from a network pharmacology approach for breast cancer therapy READ MORE HER2-positive breast cancer in patients with BRCA1/2 pathogenic variants: Case series and literature review READ MORE Larotrectinib in NTRK3 fusion–positive metastatic secretory carcinoma of the breast: A case study READ MORE Lichenoid dermatitis induced by abemaciclib in a patient with HR+/HER2- breast cancer READ MORE Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients READ MORE The usefulness of CanAssist Breast over Ki67 in breast cancer recurrence risk assessment READ MORE Surgical Management of Breast Cancer Liver Metastasis READ MORE The optimal timing of breast cancer surgery after COVID-19 infection: an observational study READ MORE Genomic tests for risk stratification in patients with early human epidermal growth factor receptor 2-positive breast cancer READ MORE Concordant and discordant breast density patterns by different approaches for assessing breast density and breast cancer risk READ MORE Incidence and risk factors of pain following breast cancer surgery: a retrospective national inpatient sample database study READ MORE Hormone Receptor Positive Breast Cancer in Young Women: A Review READ MORE Higher risk of recurrence in early-stage breast cancer patients with increased levels of ribosomal protein S6 READ MORE Development and validation of a gene expression-based Breast Cancer Purity Score READ MORE Epigenetic aging differentially impacts breast cancer risk by self-reported race READ MORE Senescence-related genes as prognostic indicators in breast cancer survival READ MORE Clinical Impact of Somatic Genomic Testing on Breast Cancer Care READ MORE Could macrocytosis predict survival In advanced breast cancer patients that were treated with CDK 4–6 inhibitors? READ MORE Pathological complete response after neoadjuvant cyclin-dependent kinase 4/6 inhibitor and neoadjuvant endocrine therapy in locally advanced hormone receptor-positive breast cancer READ MORE Distinct salivary antioxidant patterns linked to breast cancer molecular subtypes READ MORE Therapeutic Response and Toxicity of Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 Negative Metastatic Breast Cancer–A Single-Center Experienced READ MORE Optimized biomarker evaluation and molecular testing in the era of breast cancer precision medicine READ MORE Triple-Negative Breast Cancer: Molecular Particularities Still a Challenge READ MORE Impact of Molecular Profiling on Therapy Management in Breast Cancer READ MORE Precision medicine in breast cancer (Review) READ MORE Validation of an AI-based solution for breast cancer risk stratification using routine digital histopathology images READ MORE The Genomic Landscape of Breast Cancer in Young and Older Women READ MORE Guidelines of the Brazilian Society of Surgical Oncology for anatomopathological, immunohistochemical, and molecular testing in female tumors READ MORE A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020–present READ MORE Hormone receptor-positive early breast cancer in young women: A comprehensive review READ MORE Frequency of use and characterization of frailty assessments in observational studies on older women with breast cancer: a systematic review READ MORE What are the needs in oral antitumor therapy? An analysis of patients’ and practitioners’ preferences READ MORE Artificial intelligence on breast cancer risk prediction READ MORE Single institution retrospective review of patients with metastatic hormone receptor positive breast cancer receiving first line therapy of CDK4/6 inhibitors. READ MORE Frequency of dose reductions of abemaciclib in metastatic and early-stage hormone positive, HER2 negative breast cancer. READ MORE CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety READ MORE Incidental pathogenic germline alterations detected through liquid biopsy in patients with solid tumors: prevalence, clinical utility and implications READ MORE Role of Breast Cancer Risk Estimation Models to Identify Women Eligible for Genetic Testing and Risk-Reducing Surgery READ MORE Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer READ MORE Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients READ MORE Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway READ MORE Polypharmacy and drug-drug interactions in metastatic breast cancer patients receiving cyclin-dependent kinase (CDK) 4/6 inhibitors READ MORE Research Status of Systemic Adjuvant Therapy for Early Breast Cancer READ MORE Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib READ MORE Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer READ MORE Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial READ MORE Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort READ MORE Estimating the Cost of 3 Risk Prediction Strategies for Potential Use in the United Kingdom National Breast Screening Program READ MORE Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial READ MORE Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial READ MORE Training health workers in clinical breast examination for early detection of breast cancer in low‐ and middle‐income countries READ MORE European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care READ MORE CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective READ MORE Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial READ MORE Clinical significance of circulating tumor cell (CTC)-specific microRNA (miRNA) in breast cancer READ MORE Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review READ MORE Cancer Biomarkers in Liquid Biopsy for Early Detection of Breast Cancer: A Systematic Review READ MORE Comparison of overall survival after neoadjuvant and adjuvant chemotherapy in patients with early breast cancer with immediate breast reconstruction after mastectomy: A retrospective, matched case‑control study READ MORE An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low) READ MORE Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer READ MORE CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review) READ MORE Facebook Twitter Linkedin
